Published in Hum Pathol on April 01, 2005
Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South-West France. Virchows Arch (2007) 0.92
Hepatitis E: a complex and global disease. Emerg Health Threats J (2008) 0.89
Hepatitis E in liver biopsies from patients with acute hepatitis of clinically unexplained origin. Front Physiol (2013) 0.86
Clinical features and risk factors of acute hepatitis E with severe jaundice. World J Gastroenterol (2012) 0.86
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology (2011) 3.81
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology (2013) 2.78
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum (2004) 2.44
Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol (2008) 2.44
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nat Med (2007) 2.28
Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood (2002) 2.08
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations. Virchows Arch (2012) 1.63
Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci U S A (2002) 1.63
Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood (2007) 1.59
Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. Gastroenterology (2003) 1.53
Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res (2006) 1.52
Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. Am J Gastroenterol (2008) 1.52
Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol (2002) 1.49
Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol (2007) 1.46
Angiotropic neonatal congenital melanocytic nevus: how extravascular migration of melanocytes may explain the development of congenital nevi. Am J Dermatopathol (2010) 1.46
Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther (2006) 1.45
The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch (2010) 1.44
In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol (2005) 1.44
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev (2002) 1.43
Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest (2008) 1.42
Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res (2013) 1.36
An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol (2008) 1.34
Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol (2005) 1.33
Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res (2013) 1.33
Assessment of MRI and MRCP in diagnosis of biliary cystadenoma and cystadenocarcinoma. Eur Radiol (2005) 1.30
TP53 status and response to chemotherapy in breast cancer. Pathobiology (2008) 1.28
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med (2011) 1.23
Lynch or not Lynch? Is that always a question? Adv Cancer Res (2012) 1.22
Th17/Treg ratio in human graft-versus-host disease. Blood (2010) 1.19
Overexpression of endocan induces tumor formation. Cancer Res (2003) 1.19
Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. Cancer (2008) 1.17
Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res (2013) 1.16
Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med (2010) 1.16
Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. Arch Dermatol (2006) 1.16
Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression. Proc Natl Acad Sci U S A (2009) 1.13
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat (2010) 1.13
Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis (2005) 1.12
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene (2002) 1.10
Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell Oncol (Dordr) (2011) 1.09
Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J Clin Oncol (2007) 1.08
Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res (2010) 1.07
Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest (2004) 1.07
Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch (2004) 1.07
A functional sequence-specific interaction between influenza A virus genomic RNA segments. Proc Natl Acad Sci U S A (2013) 1.06
High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Virchows Arch (2002) 1.06
p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast (2013) 1.05
Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood (2003) 1.05
In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med (2002) 1.04
Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer (2012) 1.04
Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood (2003) 1.02
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res (2007) 1.02
Donor-derived cells and human graft-versus-host disease of the skin. Blood (2006) 1.01
p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer (2009) 1.01
Abnormal expression of M1/MUC5AC mucin in distal colon of patients with diverticulitis, ulcerative colitis and cancer. Int J Cancer (2007) 1.01
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res (2011) 1.00
Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol (2007) 1.00
Critical role of segment-specific packaging signals in genetic reassortment of influenza A viruses. Proc Natl Acad Sci U S A (2013) 1.00
TP53 status and response to treatment in breast cancers. J Biomed Biotechnol (2011) 0.99
Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood (2011) 0.98
Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One (2012) 0.98
Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med (2010) 0.98
Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation (2011) 0.98
Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene (2003) 0.98
Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood (2008) 0.98
EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res (2011) 0.98
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist (2010) 0.97
Breast intracystic papillary carcinoma: an update. Breast J (2009) 0.97
TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine (2011) 0.96
Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood (2003) 0.96
Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles. Virology (2011) 0.95
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer (2013) 0.95
Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. Radiology (2006) 0.95
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood (2008) 0.95
Protective effects of S-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease. Am J Physiol Lung Cell Mol Physiol (2006) 0.95
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB J (2008) 0.94
Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis (2007) 0.93
Genotype/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms. PLoS One (2012) 0.93
Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. J Hematol Oncol (2012) 0.93
Pericapillary hemorrhage as criterion of severe human digestive graft-versus-host disease. Blood (2004) 0.93
Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood (2012) 0.92
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res (2013) 0.92
Clinical severity scores in gastrointestinal graft-versus-host disease. Transplantation (2014) 0.92
Peripheral T-cell lymphoma with eosinophilia presenting as monoarthritis: a case study. Leuk Lymphoma (2002) 0.92
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood (2013) 0.92